Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0Y5LX
|
||||
| Former ID |
DNC010611
|
||||
| Drug Name |
4-cyclohexyl-6-propylpyrimidine-2-carbonitrile
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C14H19N3
|
||||
| Canonical SMILES |
CCCC1=NC(=NC(=C1)C2CCCCC2)C#N
|
||||
| InChI |
1S/C14H19N3/c1-2-6-12-9-13(17-14(10-15)16-12)11-7-4-3-5-8-11/h9,11H,2-8H2,1H3
|
||||
| InChIKey |
WGTHPYHNMKDPLN-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Cathepsin K | Target Info | Inhibitor | [1] | |
| KEGG Pathway | Lysosome | ||||
| Osteoclast differentiation | |||||
| Toll-like receptor signaling pathway | |||||
| Rheumatoid arthritis | |||||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | ||||
| RANKL Signaling Pathway | |||||
| IL2 Signaling Pathway | |||||
| Reactome | Collagen degradation | ||||
| Degradation of the extracellular matrix | |||||
| Activation of Matrix Metalloproteinases | |||||
| Trafficking and processing of endosomal TLR | |||||
| MHC class II antigen presentation | |||||
| WikiPathways | RANKL/RANK Signaling Pathway | ||||
| Osteoclast Signaling | |||||
| References | |||||
| REF 1 | Bioorg Med Chem Lett. 2010 Mar 1;20(5):1524-7. Epub 2010 Jan 25.Design and optimization of a series of novel 2-cyano-pyrimidines as cathepsin K inhibitors. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.